Most are longWith 55.5 million shares out, i believe 20-25% of the float comprises of short term traders. It's just the way it is with even good stories. Stocks provide a pricing range that allows for trading entry and exit with a spread for profitability. Keep in mind this stock was basically at 20 cents post rollback for a very long time and a lot of money was raised in Dec at the equivalent of 20 and 30 cents respectively. I'm here for the hold. I believe the stock is heavily discounted still because of the prolonged negative stall cycle it has gone through (years). The coming out party will be the midpoint data thats expected in February. By all accounts, the data should be good as prior historical data has been favorable. Truth be told, with what's under the hood, 10 years of data and 91 patents in addition to a live phase 2 fda clinical under orphan status, this stock should be trading at a minimum of $2 even from a conservative standpoint. In the smallcap bio tech space, especially in Canada, valuations rarely reflect the same way as it does Stateside. So, in my opinion, buy and hold is a reasonable choice given the dynamics of what appears to be a fluid situation of upcoming catalysts.